Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells.

[1]  H. Woo,et al.  Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. , 2013, Cell reports.

[2]  M. Loda,et al.  EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent , 2012, Science.

[3]  P. Atadja,et al.  Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation , 2012, Proceedings of the National Academy of Sciences.

[4]  D. Noh,et al.  EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex. , 2012, Molecular cell.

[5]  Tim J. Wigle,et al.  A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. , 2012, Nature chemical biology.

[6]  Yan Liu,et al.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.

[7]  Guang-Yuh Chiou,et al.  Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis , 2012, Journal of cellular physiology.

[8]  Qiang Yu,et al.  Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. , 2011, Molecular cell.

[9]  L. D. Croce,et al.  Roles of the Polycomb group proteins in stem cells and cancer , 2011, Cell Death and Disease.

[10]  Erika Pastrana,et al.  Eyes wide open: a critical review of sphere-formation as an assay for stem cells. , 2011, Cell stem cell.

[11]  R. McLendon,et al.  Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. , 2011, Cancer cell.

[12]  G. Stark,et al.  Lysine methylation of promoter-bound transcription factors and relevance to cancer , 2011, Cell Research.

[13]  D. Reinberg,et al.  The Polycomb complex PRC2 and its mark in life , 2011, Nature.

[14]  G. Stark,et al.  Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes , 2010, Proceedings of the National Academy of Sciences.

[15]  P. Dirks,et al.  Brain tumor stem cells: The cancer stem cell hypothesis writ large , 2010, Molecular oncology.

[16]  E. Hurt,et al.  Clinical significance of Polycomb gene expression in brain tumors , 2010, Molecular Cancer.

[17]  M. Wolter,et al.  Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas , 2010, International journal of cancer.

[18]  K. Helin,et al.  Polycomb group protein-mediated repression of transcription. , 2010, Trends in biochemical sciences.

[19]  Yonghong Xiao,et al.  PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. , 2010, Cancer cell.

[20]  Jane Fridlyand,et al.  Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. , 2010, Cancer research.

[21]  G. Stark,et al.  Regulation of NF-κB by NSD1/FBXL11-dependent reversible lysine methylation of p65 , 2009, Proceedings of the National Academy of Sciences.

[22]  Wei Keat Lim,et al.  The transcriptional network for mesenchymal transformation of brain tumors , 2009, Nature.

[23]  Nicolò Riggi,et al.  EZH2 is essential for glioblastoma cancer stem cell maintenance. , 2009, Cancer research.

[24]  A. Ross,et al.  Cancer stem cells: Cell culture, markers, and targets for new therapies , 2009, Journal of cellular biochemistry.

[25]  Guido Nikkhah,et al.  NOTCH Pathway Blockade Depletes CD133‐Positive Glioblastoma Cells and Inhibits Growth of Tumor Neurospheres and Xenografts , 2009, Stem cells.

[26]  B. Cochran,et al.  STAT3 Is Required for Proliferation and Maintenance of Multipotency in Glioblastoma Stem Cells , 2009, Stem cells.

[27]  Robert E. Kingston,et al.  Mechanisms of Polycomb gene silencing: knowns and unknowns , 2009, Nature Reviews Molecular Cell Biology.

[28]  Justin C. Grindley,et al.  Tumour-initiating cells: challenges and opportunities for anticancer drug discovery , 2009, Nature Reviews Drug Discovery.

[29]  G. Bernier,et al.  BMI1 Sustains Human Glioblastoma Multiforme Stem Cell Renewal , 2009, The Journal of Neuroscience.

[30]  Mark Bernstein,et al.  Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. , 2009, Cell stem cell.

[31]  H. Fine,et al.  SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. , 2009, Cell stem cell.

[32]  Fang Liu,et al.  Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells. , 2009, Cancer research.

[33]  P. Yue,et al.  Targeting STAT3 in cancer: how successful are we? , 2009, Expert opinion on investigational drugs.

[34]  J. Simon,et al.  Roles of the EZH2 histone methyltransferase in cancer epigenetics. , 2008, Mutation research.

[35]  Gordon B Mills,et al.  Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers , 2008, Molecular carcinogenesis.

[36]  G. Stark,et al.  Roles of unphosphorylated STATs in signaling , 2008, Cell Research.

[37]  Yuri Kotliarov,et al.  Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. , 2008, Cancer cell.

[38]  L. Chin,et al.  Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.

[39]  T. Mikkelsen,et al.  Genome-wide maps of chromatin state in pluripotent and lineage-committed cells , 2007, Nature.

[40]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[41]  D. Frank.  STAT3 as a central mediator of neoplastic cellular transformation. , 2007, Cancer letters.

[42]  Qiang Yu,et al.  Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. , 2007, Genes & development.

[43]  M. Fraga,et al.  The Polycomb group protein EZH2 directly controls DNA methylation , 2007, Nature.

[44]  Zohar Yakhini,et al.  Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer , 2007, Nature Genetics.

[45]  P. Laird,et al.  Epigenetic stem cell signature in cancer , 2007, Nature Genetics.

[46]  G. Broggi,et al.  Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells , 2006, Nature.

[47]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[48]  Anke Sparmann,et al.  Polycomb silencers control cell fate, development and cancer , 2006, Nature Reviews Cancer.

[49]  S. Berger,et al.  Repression of p53 activity by Smyd2-mediated methylation , 2006, Nature.

[50]  J. Zeitlinger,et al.  Polycomb complexes repress developmental regulators in murine embryonic stem cells , 2006, Nature.

[51]  William A Weiss,et al.  A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. , 2006, Cancer cell.

[52]  Yuri Kotliarov,et al.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. , 2006, Cancer cell.

[53]  Megan F. Cole,et al.  Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells , 2006, Cell.

[54]  M. Hung,et al.  Akt-Mediated Phosphorylation of EZH2 Suppresses Methylation of Lysine 27 in Histone H3 , 2005, Science.

[55]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[56]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[57]  Ugo Orfanelli,et al.  Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma , 2004, Cancer Research.

[58]  Daniel H. Geschwind,et al.  Cancerous stem cells can arise from pediatric brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[59]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[60]  D. Reinberg,et al.  Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. , 2002, Genes & development.

[61]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[62]  Hengbin Wang,et al.  Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.

[63]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[64]  R. Kingston,et al.  Stabilization of Chromatin Structure by PRC1, a Polycomb Complex , 1999, Cell.

[65]  S. Akira,et al.  Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway , 1994, Cell.

[66]  J. Darnell,et al.  Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. , 1994, Science.

[67]  Tzong-Shiue Yu,et al.  A restricted cell population propagates glioblastoma growth after chemotherapy , 2012 .

[68]  S. Orkin,et al.  PRC2 directly methylates GATA4 and represses its transcriptional activity. , 2012, Genes & development.

[69]  W. Weiss,et al.  Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. , 2010, Current topics in microbiology and immunology.

[70]  V. Preedy,et al.  European Organization for Research and Treatment of Cancer , 2010 .

[71]  J. Uhm,et al.  The transcriptional network for mesenchymal transformation of brain tumours , 2010 .

[72]  R. McLendon,et al.  Erythropoietin Receptor Signaling Through STAT3 Is Required For Glioma Stem Cell Maintenance. , 2010, Genes & cancer.

[73]  Yuan Qi,et al.  Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA , IDH 1 , EGFR , and NF 1 Citation Verhaak , 2010 .

[74]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[75]  J. Uhm.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .

[76]  D. Louis.  WHO classification of tumours of the central nervous system , 2007 .

[77]  Zang Ai-hua,et al.  Stem Cells,Cancer and Cancer Stem Cells , 2005 .